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ABSTRACT 
Many proteins involved in cell signaling are phosphorylated. To determine the 
phosphorylation status of these signaling molecules at the single-cell level, we present 
a protocol for using state-specific antibodies to detect target phosphoproteins  with 
fluorescence measurements by flow cytometry. To improve the signal intensity, a 
sandwich-labeling method for the analysis of signaling proteins is performed. By 
comparing the phosphorylation state of proteins in the presence and absence of sodium 
pervandate, a nonspecific protein tyrosine phosphatase inhibitor, we determined the 
relative amount of tyrosine phosphorylated protein in the samples, which reflects the 
activity of the signaling pathway. This dynamic approach in combination with the 
signal amplification through a sandwich-labeling method, increased the accuracy and 
reproducibility of the measurements compared to a single analysis avoiding internal 
controls defining the maximum level of phosphorylation.  
 
INTRODUCTION 
Intracellular phosphorylated proteins (phosphoproteins) are actors in cellular 
processes, spanning from signal transduction to cell metabolism, cell cycle control, 
development, and differentiation. The activity of many signaling proteins is regulated 
by phosphorylation of serine, threonine, or tyrosine residues, or some combination 
thereof. These phosphorylation changes are posttranslational events that are controlled 
by the combined action of two opposing enzymes, protein phosphatases and kinases 
(1).  
The clinical importance of protein phosphorylation is underlined by the fact that 
several protein kinases have been implicated in cancer as oncogenes, and this activity 
is antagonized by phosphatases, functioning as tumor suppressors (2). One example is 
the phosphatidylinositol 3-kinase (PI3K) to Akt axis a signaling pathway that is 
controlled by phosphorylation-dephosphorylation mechanisms and appears to be 
altered in several diseases, including cancer (3). Tumor cells and immortalized cell 
lines typically present aberrant activation signaling events compared to those in 
samples from healthy animals or patients (4).  
Gene expression and protein abundance profiling experiments do not necessarily 
assess protein activity (5, 6). For proteins with functions that are controlled by 
phosphorylation,  the experimental determination of residues that can be 
phosphorylated, as well as their phosphorylation state are important (1). For proteins 
that are activated by specific phosphorylation events, measuring the phosphorylation 
state of the protein is a reliable indicator of activity. Thus, the determination of 
activation status of intracellular signaling phosphoproteins provides additional layers 
of information compared with information obtained through transcriptional and 
protein profiling studies. Methods that facilitate assessment of phosphoprotein status 
not only contribute to our understanding of cell signaling mechanisms, but may also 
have roles in the development and implementation of personalized cancer therapies. 
Methods for ascertaining robust measurements of the phosphorylation state of 
intracellular signaling proteins in single primary tumor cells with the sensitivity, 
specificity, and precision are needed to provide clinically useful information.  
We present a dynamic phosphoflow proteomic method that uses state-specific 
antibodies to detect target phosphoproteins by fluorescence-activated cell sorting 
(FACS).  We assess the activity of the signaling pathways following exposure of the 
cells to either the pleiotropic chemical sodium pervanadate, which inhibits protein 
tyrosine phosphatases (7), or to specific kinase inhibitors. For cells exposed to 
pervanadate, proteins that are relatively unphosphorylated (inactive under basal 
conditions) will exhibit a large increase in the abundance of the phosphorylated form 
upon pervanadate treatment; whereas those proteins that are already phosphorylated 
(active under basal conditions) will exhibit only a limited increase in the abundance of 
the phosphorylated form following pervanadate treatment (Fig. 1A).  For cells 
exposed to a specific inhibitor, phosphoflow analysis reveals whether a particular 
signaling pathway is already activated or not (Fig. 1B).  
In addition, this method can be used to screen new compounds and identify signaling 
targets in drug discovery. To illustrate both the use of pervanadate and a specific 
inhibitor, we describe the application of either pervanadate or wortmannin, an 
antifungal antibiotic that inactivates PI3K (8) to the human monocytic cell line U937 
(cells with a PTEN mutation) or the human erythromyeloblastoid leukemia cell line 
K562  (cells with the Bcr-Abl translocation).  
To amplify the signal, we apply a sandwich-labeling method, which involves the 
application of a biotin-conjugated secondary antibody followed by detection with a 
fluorescently conjugated streptavidin (Fig. 2).  
We demonstrate the application of this method by analyzing the activity of the PI3K-
Akt pathway by measuring the phosphorylation of Akt at Ser473 and then extend the 
analysis to other signaling pathways defined by phosphorylation of other signaling 
components. As with the other methods described above, this Protocol relies on the 
availability of phosphorylation state-specific antibodies that recognize the target 
protein.   
The technique has the potential to allow the identification of the signaling state of cells 
from patients, thus facilitating the transformation of the concept of personalized 
therapy into a clinical reality. 
 
MATERIALS 
Biotin-SP-AffiniPure F(ab')2 Frag Donkey Anti-Rabbit IgG (H+L), (# 711-066-152, 
Jackson ImmunoResearch product, Beckman Coulter) secondary antibodies 
Note: Secondary antibody can be any biotin-conjugated antibody against the 
immunoglobulin class and species of phosphorylation state-specific antibodies. 
CD3-PE-Cy5  mouse anti-human CD3 monoclonal antibody (# 555334, BD 
Biosciences Pharmingen) 
CD13-FITC mouse anti-human CD13 monoclonal antibody (# IM0778U, IOTest® 
Beckman Coulter)  
Note: For detection of cell surface markers, the antibodies must be directly 
conjugated to the appropriate fluorophore. 
Fetal calf serum (FCS) (# CVFSV F00-01, Eurobio)  
Fixation and permeabilization solution (Cytofix/Cytoperm) (# 554714, BD 
Biosciences)  
Note:  This solution contains formaldehyde, a suspected carcinogen. Avoid 
contact with skin, eyes, and mucous membranes and  avoid breathing fumes. It 
can be harmful if inhaled, or by contact with skin, or if swallowed. In case of 
contact with eyes, rinse immediately with plenty of water and seek medical 
advice. Use only in well-ventilated areas.  
Flow cytometer calibration beads [Sphero™ Rainbow calibration particles (6 peaks), 
6.0-6.4 µm, (# 556288, BD Biosciences)] 
Isotype control antibody for CD3-PE-Cy5 (# 555750, BD Biosciences Pharmingen)  
Isotype control antibody for CD13-FITC (# A07795, IOTest® Beckman Coulter) 
Note: Directly conjugated isotype controls (irrelevant antibodies of the same 
immunoglobulin class and species as the relevant surface marker antibodies) 
are required negative controls. 
Isotype control antibody for phosphorylated Akt (Ser473) and phosphorylated CrkL 
(Tyr207) antibodies (# I 8140, SIGMA) 
Note: Unconjugated isotypic controls (irrelevant antibodies of the same 
immunoglobulin class and species as the relevant phosphorylation state-  
specific antibodies) are required negative controls. 
Hydrogen peroxide (H2O2) 30%   (# 23619.264, NORMAPUR Prolabo) 
Permeabilization and wash buffer (Perm/Wash Buffer) 10×, (# 554723, BD 
Biosciences)  
Phosphate-buffered saline (PBS) 10×, (# 70013065, GIBCO) 
Rabbit monoclonal antibody that recognizes phosphorylated Akt (Ser473) (clone 
193H12, (# 4058, Cell Signaling Technology) 
Rabbit monoclonal antibody that recognizes phosphorylated CrkL (Tyr207) (# 3181, 
Cell Signaling Technology) XXX primary antibodies 
Note: For detection of the phosphorylated proteins, primary antibodies can be 
any unconjugated purified phosphorylation state-specific antibodies that 
recognize the phosphoprotein target  in flow cytometry experiments.  
Roswell Park Memorial Institute (RPMI) 1640 media (# Z1875, GIBCO) 
Sodium orthovanadate, crystalline powder, ( #S6508, SIGMA)  
Note:This compound is toxic [Chemistry Abstracts Service (CAS) number,  
13721-39-6]. 
 Streptavidin conjugated with phycoerythrin (Streptavidin-PE), (# IM3325,  Beckman 
Coulter) 
Wortmannin (# 681675, Calbiochem) 
 
EQUIPMENT 
Cell culture and staining 
Standard equipment for cell culture risk group level 2 (RGL-2): laminar flow cabinet, 
CO2 incubator 37°C  
50 mL-flasks 
12-Well plates 
Pipette-Aid 
Refrigerated centrifuge fitted with buckets and adapters for centrifuging 15-mL 
conical centrifuge tubes and plate carrier for buckets for centrifuging 96-well plates 
Water bath (37°C)  
Pipetman 
Pipetman ultra multichannel 
96-well round-bottom microtiter plates 
12 × 75 mm,  5 mL polystyrene round bottom test tubes (FACS tubes) 
15 mL Polystyrene conical centrifuge tubes, (15-mL centrifuge tubes) 
Vortex 
Flow Cytometry and Data Analysis 
FACs Can flow cytometer (BD Biosciences) 
Note: The minimum requirement is a flow cytometer equipped with 488 nm 
laser. 
Computer 
Note: Data may be stored either locally on the computer attached to the flow 
cytometer or on remote analysis stations connected to a computer network that 
is also used to store flow cytometry data. 
FlowJo (BD Biosciences) or Cell Quest (BD Biosciences) 
Microsoft Excel   
 
RECIPES 
Recipe 1: RPMI-1640 -10% FCS 
Add 50 mL of sterile FCS to one 0.5 L bottle of sterile RPMI. Store at 4°C for up to 1 
month. 
Recipe 2: RPMI-1640-5% FCS 
Dilute  RPMI-1640 Medium + 10% FCS (Recipe 1) with RPMI-1640 until 5% FCS is 
achieved. 
Recipe 3: RPMI-1640-2% FCS 
Dilute RPMI-1640 Medium + 10% FCS (Recipe 1) with RPMI-1640 until 2% FCS is 
achieved. 
Recipe 4: 100 mM Sodium Orthovanadate Stock Solution 
Dissolve sodium orthovanadate to a final concentration of 100 mM in distilled water.  
Note: This may be stored for 1 year at -20°C .if the solution is adjusted for pH 
with HCl, then with NaOH(9)). 
Recipe 5: Pervanadate Solution (10 mM) 
100 mM Sodium Orthovanadate Stock Solution (Recipe 4) 20 µL  
30% H2O2   23 µL 
Mix together and then add the following: 
RPMI-1640 + 2% FCS (Recipe 3)   157 µL 
Mix and incubate for 15 minutes at room temperature in the dark before using. 
Recipe 6: Pervanadate Solution (500 µM) 
Dilute 50 µL  10 mM Pervanadate Solution (Recipe 5) into 950 µL of RPMI-1640 + 
2% FCS (Recipe 3). 
Note: This solution must be prepared immediately before use. 
Recipe 7: 1 mM Wortmannin Solution 
Dissolve wortmannin to a final concentration of 1 mM in DMSO 
Note: This may be stored for up to 2 months  at -20°C in dark. 
Recipe 8: Perm/Wash Buffer 
Prepare a fresh 1× solution by diluting 10× BD Perm/Wash Buffer stock with distilled 
water. 
Recipe 9: PBS 
Prepare a solution at 1× solution by diluting 10× PBS stock solution with distilled 
water. 
Recipe 10: Primary Antibody Solutions 
Prepare a fresh solution at 1x solution by diluting 100x rabbit monoclonal antibody 
that recognizes phosphorylated Akt(Ser473) stock solution with 1x Perm/Wash Buffer 
(Recipe 8) 
Prepare a fresh solution at 1x solution by diluting  50x rabbit monoclonal antibody 
that recognizes phosphorylated CrkL (Tyr207) stock solution with 1x Perm/Wash 
Buffer (Recipe 8) 
Prepare a fresh solution at 1x solution by diluting  48000x Isotype control antibody for 
phosphorylated antibodies stock solution with 1x Perm/Wash Buffer (Recipe 8) 
Note: The optimal dilution for other primary antibodies must be determined 
empirically or, if commercially available, should be prepared and used 
according to the manufacturer's instructions.  
Recipe 11: Secondary Antibody Solution 
Prepare a fresh solution at 1x solution by diluting 500x  Biotin-SP-AffiniPure F(ab')2 
Frag Donkey Anti-Rabbit IgG stock solution with 1x Perm/Wash Buffer (Recipe 8)  
Note: The optimal dilution for other secondary antibodies must be determined 
empirically or, if commercially available, should be prepared and used 
according to the manufacturer's instructions.  
Recipe 12: Streptavidin-PE Solution 
Prepare a fresh solution at 1x solution by diluting 50x  Streptavidin conjugated with 
phycoerythrin stock solution with 1x Perm/Wash Buffer (Recipe 8)  
Note: The optimal dilution for streptavindin-PE must be determined 
empirically or, if commercially available, should be prepared and used 
according to the manufacturer's instructions.  
Recipe 13: Directly Conjugated  Antibody Solutions  
Prepare a fresh solution at 1x solution by diluting 50x  CD3-PE-Cy5  mouse anti-
human CD3 monoclonal antibody stock solution with PBS (Recipe 9)   
Prepare a fresh solution at 1x solution by diluting 50x CD13-FITC mouse anti-human 
CD13 monoclonal antibody stock solution with PBS (Recipe 9)   
Prepare a fresh solution at 1x solution by diluting 50x Isotype control antibody for 
CD3-PE-Cy5 stock solution with PBS (Recipe 9)   
Prepare a fresh solution at 1x solution by diluting 50x Isotype control antibody for 
CD13-FITC stock solution with PBS (Recipe 9)   
Note: The optimal dilution for other directly  conjugated antibodies must be 
determined empirically or, if commercially available, should be prepared and 
used according to the manufacturer's instructions.  
Recipe 14: Flow Cytometer Calibration Beads  
In a FACS tube, resuspend one drop of (~20 µL) flow cytometer  calibration beads 
into 500 µL of 1× PBS (Recipe 9). 
 
INSTRUCTIONS 
Cell Preparation 
Cell lines or primary cells may be analyzed by dynamic phosphoflow cytometry. We 
provide details for the analysis of the human monocytic cell line U937 (cells with a 
PTEN mutation), the human erythromyeloblastoid leukemia cell line K562 (cells with 
the Bcr-Abl translocation), and the human T cell line HUT78.  
Note: This protocol can be used with primary cells such as peripheral blood 
mononuclear cells (PBMCs) (from freshly isolated cells or thawed frozen samples). 
For commercially available cell lines, we recommend following the supplier's 
instructions regarding culture medium and growth conditions, for example, any 
supplements to the growth medium and conditions for passaging the cells. However, it 
is important that the cells are suspended in a medium with a low concentration of 
calcium, such as RPMI medium, for analysis. Thus, cells grown in Dulbecco’s 
modified Eagle medium (DMEM) should be transferred to RPMI-based medium when 
they are collected for analysis. 
Ideally, negative- and positive-control cells for which the phosphorylation status of the 
target protein under the experimental conditions is known, as well as the test cells for 
which the phosphorylation status of the target protein will be determined, should be 
analyzed.  
1. Count the cells using Trypan Blue to determine cell viability  
2. Resuspend cultured cells at a final concentration of 1 × 106  cells/mL in RPMI-10% 
FCS (Recipe 1). 
Note: From 3x10 6 cells we can analyze 5 to 10  phosphoproteins per cell type and 
per two conditions (UT and treated) in single staining. 
Note: From 3.3x10 6 cells we can analyze 5 to 10  phosphoproteins per cell type 
and per two conditions (UT and treated) in multiparameter staining for a 
combinaison of 3 fluorochromes.. 
  
3. Transfer 10 mL of the cell suspension to a 50 mL-size flask and incubate at 37°C, 
5% CO2 for 24 hours. 
Note: Cultured cells should be in the logarithmic growth phase. Adherent cells 
should be passed 2 to 3 days prior to analysis and cells should be 70 to 85% 
confluent when collected for analysis. 
 
Pretreatment of Cells with Inhibitors 
Any cell-permeable kinase or phosphatase inhibitor can be used. We describe the 
application of pervanadate (to analyze the activity of signalling pathways involving 
tyrosine phosphorylation) and wortmannin (to analyze the activity of pathways 
downstream of PI3K).  
Pervanadate pretreatment 
1.  Count the cells using Trypan Blue to determine cell viability. 
2.  Transfer cell suspension to a 15-mL centrifuge tube.  
3.  Centrifuge the cell suspension at 420g for 5 min at 4°C.  
4.  Resuspend the cell pellet at a final concentration of 1 × 106 cells/mL in RPMI-5%  
FCS (Recipe 2).  
5.  Plate cell suspension in one well of a well plate. 
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10  phosphoproteins per cell type and per two 
conditions (UT and treated)  in single staining, plate 3x10 6 cells /3 mL of cell 
suspension in one well of a 12-well plate. For a combinaison of 3 
fluorochromes in multiparameter staining plate 3.3x10 6 cells /3.3 mL of cell 
suspension. 
6.  Incubate covered plate at 37°C for 1 hour.  
7.  Transfer cell suspensions to 15-mL centrifuge tubes.  
8.  Centrifuge at 420g for 5 minutes at 4°C.  
9.  Place the tubes on ice.  
10.  Remove the supernatant with a suction system. 
11.  Resuspend cells in cold RPMI-2% FCS (Recipe 3).  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10  phosphoproteins per cell type and per two 
conditions (UT and treated)  in single staining resuspend the 3x10 6 cells in 
150 µL of cold RPMI-2% FCS. For a combinaison of 3 fluorochromes in 
multiparameter staining resuspend the 3.3x10 6 cells with 165µL. 
12.  Label two FACS tubes [untreated cells (UT), pervanadate-treated cells (pV)] and 
place tubes on ice. 
13.  Transfer cell suspension to FACS (UT) and (pV) and keep on ice until ready to 
proceed.  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10 phosphoproteins per cell type and per two 
conditions (UT and treated) in single staining transfer 100 µL (2x10 6 cells) of 
cell suspension to FACS (UT) and 50 µL (1x10 6 cells) to FACS (pV). For a 
combinaison of 3 fluorochromes in multiparameter phosphoproteins transfer 
115µL (2.3x10 6 cells) of cell suspension to FACS (UT) and 50µL(1x10 6 cells) 
to FACS (pV). 
14.  Transfer all tubes in 37°C water bath and incubate 1 minute. 
15. Add Pervanadate Solution (500 µM) (Recipe 6) to the pV sample and mix well.  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10 phosphoproteins in single staining or in 
multiparameter (3 fluorochromes) staining add 5 µL of Pervanadate to FACS 
(pV) in the 50µL(1x10 6 cells) of cell suspension.  
16.  Add RPMI-2% FCS (Recipe 3) to the UT samples and mix well.  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10 phosphoproteins in single staining add 10 µL 
of RPMI-2% FCS to FACS (UT) and for multiparameter (3 fluorochromes) 
staining add 11.5 µL .  
17.  Incubate 5 minutes at 37°C. 
18. Add pre-warmed Cytofix/Cytoperm to all samples, mix, and incubate 10 minutes 
at 37°C. 
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10 phosphoproteins per cell type and per two 
conditions (UT and treated) in single staining add 100µL (2x10 6 cells) of pre-
warmed Cytofix/Cytoperm to FACS (UT) and 50µL (1x10 6 cells) to FACS 
(pV). For a combinaison of 3 fluorochromes in multiparameter 
phosphoproteins add 115µL (2.3x10 6 cells) to FACS (UT) and 50µL(1x10 6 
cells) to FACS (pV). 
19.  Remove tubes from the water bath and place in a rack at room temperature (RT).  
20. Add 1× Perm/Wash Buffer (Recipe 8) to each sample.  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10 phosphoproteins per cell type and per two 
conditions (UT and treated) in single staining respectively adjust to 2mL and 
4mL with 1× Perm/Wash Buffer to FACS (UT) and to 1mL and 2mL to FACS 
(pV). For a combinaison of 3 fluorochromes in multiparameter 
phosphoproteins respectively adjust to 2.3mL and 4.6mL with 1× Perm/Wash 
Buffer to FACS (UT) and to 1mL and 2mL to FACS (pV).  
Wortmannin pretreatment  
1.  Count the cells using Trypan Blue to determine cell viability. 
2.  Transfer cell suspension to a 15-mL polystyrene conical centrifuge tube.  
3.  Centrifuge the cell suspension at 420g for 5 min at 4°C.  
4.  Resuspend the cell pellet at a final concentration of 1 × 106 cells/mL in RPMI-5% 
FCS (Recipe 2).  
5.  Label two wells [untreated cells (UT), inhibitor-treated cells (Inhibitor)] of a well 
plate. 
6. Plate cell suspension in two wells of a well plate. 
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10  phosphoproteins per cell type and per two 
conditions (UT and treated)  in single staining, plate 2mL (2x10 6 cells) of cell 
suspension to UT  well and 1mL (1x10 6 cells) to Inhibitor well . For a 
combinaison of 3 fluorochromes in multiparameter staining plate 2.3mL 
(2.3x10 6 cells) to UT well and 1mL (1x10 6 cells) to Inhibitor well. 
7.  Add Wortmannin Solution (Recipe 7) to each "inhibitor" well and mix gently with 
a micropipette. 
Note: The optimal conditions for other Inhibitors must be determined 
empirically or, if commercially available, should be prepared and used 
according to the manufacturer's instructions.  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10 phosphoproteins in single staining or in 
multiparameter (3 fluorochromes) staining add 1 µL of Wortmannin to 
Inhibitor well in the 1mL (1x10 6 cells) of cell suspension .  
8.  Incubate covered plate at 37°C for 1 hour.  
9.  Label two 15-mL centrifuge tubes [untreated cells (UT), Inhibitor-treated cells 
(Inhibitor)]. 
10. Transfer cell suspension to 15-mL centrifuge tubes.  
11.  Centrifuge at 420g for 5 minutes at 4°C.  
12.  Place the tubes on ice.  
13.  Remove the supernatant with a suction system.  
14.  Resuspend cells in cold RPMI-2% FCS (Recipe 3). 
 Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10  phosphoproteins per cell type and per two 
conditions (UT and treated)  in single staining resuspend cells  in 100 µL for 
UT  and in 50 µL for Inhibitor-treated cells of cold RPMI-2% FCS. For a 
combinaison of 3 fluorochromes in multiparameter staining resuspend cells 
cells  in 115 µL for UT  and in 50 µL for Inhibitor-treated cells. 
15.  Label two FACS tubes [untreated cells (UT), inhibitor-treated cells (Inhibitor)] 
and place tubes on ice. 
16.  Transfer the appropriate cell suspensions to the FACS tubes (UT) and (Inhibitor) 
and place in a 37°C water bath. .  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10  phosphoproteins per cell type and per two 
conditions (UT and treated)  in single staining transfer the 100 µL of cell 
suspension  to FACS (UT)  and the 50 µL to FACS Inhibitor. For a 
combinaison of 3 fluorochromes in multiparameter staining transfer the 115 
µL for UT  and the 50 µL to FACS (Inhibitor). 
17.  Incubate for 6 min at 37°C. 
18.  Add pre-warmed Cytofix/Cytoperm to all samples, mix well, and incubate 10 
minutes at 37°C.  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10 phosphoproteins per cell type and per two 
conditions (UT and treated) in single staining add 100µL (2x10 6 cells) of pre-
warmed Cytofix/Cytoperm to FACS (UT) and 50µL (1x10 6 cells) to FACS 
(Inhibitor). For a combinaison of 3 fluorochromes in multiparameter 
phosphoproteins add 115µL (2.3x10 6 cells) to FACS (UT) and 50µL(1x10 6 
cells) to FACS (Inhibitor).  
19.  Remove tubes from the water bath and place in a rack at room temperature (RT).  
20. Add 1× Perm/Wash Buffer to each sample.  
Note:  The volume depends on the number of phosphoproteins to be analyzed. 
For example, to analyze 5 to 10 phosphoproteins per cell type and per two 
conditions (UT and treated) in single staining respectively adjust to 2mL and 
4mL with 1× Perm/Wash Buffer to FACS (UT) and to 1mL and 2mL to FACS 
(Inhibitor). For a combinaison of 3 fluorochromes in multiparameter 
phosphoproteins respectively adjust to 2.3mL and 4.6mL with 1× Perm/Wash 
Buffer to FACS (UT) and to 1mL and 2mL to FACS (Inhibitor).  
Antibody Staining 
Samples may be permeabilized, fixed, and analyzed following intracellular staining of 
the target phosphoprotein(s) or the samples may be additionally labelled with 
antibodies that recognize cell surface markers. This latter staining process is optional, 
but does allow the cells to be sorted by surface markers.  
Cytofix/Cytoperm and Perm/Wash Buffer contain the detergent saponin. 
Because saponin-mediated cell permeabilization is a reversible process, it is 
important to keep the cells in the presence of saponin during both the staining 
and washing steps. 
Staining is performed in 96-well round bottom microtiter plates. To minimize 
cross-contamination during staining, we recommend that sample-filled wells 
be surrounded by empty wells on all sides. Negative-and positive-control cells 
should also be included. To analyze one phosphoprotein per cell type and per 
inhibitor in a single stain, 3 wells will be prepared (Fig. 3A):   
• UT sample plus the isotype control antibody 
• UT sample plus the antibody against the target phosphoprotein 
• Inhibitor-treated sample (pV or Inhibitor) plus the antibody against the 
target phosphoprotein 
To perform labelling of the intracellular phosphoprotein and cell surface 
markers, then a combination of fluorochromes with nonoverlapping spectra 
may be used. PE is always used to detect the intracellular phosphoprotein. For 
example, a combination of 3 fluorochromes may be used and monitored in 
different channels of the flow cytometer (represented as FLn, where n is the 
channel number): fluorescein isothiocyanate (FITC) in FL1, PE in FL2, and 
PE-Cy5 in FL3. We have used a FITC-labeled antibody that recognizes the 
myeloid surface antigen CD13 and a PE-Cy5-labeled antibody that recognizes 
the T cell surface antigen CD3. To perform this type of multiparameter 
analysis and to analyze one phosphoprotein per cell type and per inhibitor 6 
wells will be prepared (Fig. 3B):    
• UT sample plus the isotype control antibody for the FITC-, PE-Cy5- 
surface directly conjugated antibodies and for PE- intracellular 
antibody 
• UT sample plus the FITC-, PE-Cy5- directly conjugated antibodies 
against the target surface markers and PE- intracellular antibody against 
the target phosphoprotein 
• Inhibitor-treated sample (pV or Inhibitor) plus the FITC-, PE-Cy5- 
directly conjugated antibodies against the target surface markers and 
PE- intracellular antibody against the target phosphoprotein 
• UT sample plus FITC- directly conjugated antibody against the target 
surface marker only (for compensation) 
• UT sample plus PE-Cy5- directly conjugated antibody against the 
target surface marker only (for compensation) 
• UT sample plus PE- antibody against the target phosphoprotein only 
(for compensation) 
Intracellular phosphoprotein staining 
1.  Prepare 96-well round-bottom microtiter plates labelled such that the samples will 
be surrounded by empty wells.  
2.  Vortex cell suspensions and plate 200 µL of cell suspension per well in a 96-well 
round-bottom microtiter plate. 
Note:Depending on the volume of PermWash buffer (Inhibitor pre-treatment steps#  
20), the cell number is the 96-well plates will be 2x10 5 cells/well from cell suspension 
at 1x10 6 cell/mL or 1x10 5 cells/well from cell suspension at 0.5x10 6 cell/mL 
3.  Centrifuge at RT at 670g for 3 min. 
4.  Quickly flick into sink and immediately invert the plate on a paper towel  
5.  Add 100 µL of primary antibody solution [isotype control antibody (Recipe 10) or 
antibody against the target phosphoprotein (Recipe 10)] to the appropriate well(s) and 
mix by gently pipetting at least 3 times.  
6.  Incubate for 20 min at RT.  
7.  Centrifuge at RT at 670g for 3 min. 
8.  Quickly flick into sink and immediately invert the plate on a paper towel . 
9.  Add 200 µL of Perm/Wash Buffer per well and mix by gently pipetting at least 3 
times.  
10. Centrifuge at RT at 670g for 3 min. 
11. Quickly flick into sink and immediately invert the plate on a paper towel . 
12. Add 100 µL of biotin-conjugated secondary antibody solution (Recipe 11) per well 
and mix by gently pipetting at least 3 times. 
13.  Incubate for 20 min at RT.  
14. Centrifuge at RT at 670g for 3 min. 
15. Quickly flick into sink and immediately invert the plate on a paper towel . 
16. Add 200 µL of Perm/Wash Buffer per well and mix by gently pipetting at least 3 
times. 
17. Centrifuge at RT at 670g for 3 min. 
18. Quickly flick into sink and immediately invert the plate on a paper towel. 
19. Add100 µL of Streptavidin-PE Solution (Recipe 12) per well and mix by gently 
pipetting at least 3 times. 
20.  Incubate for 15 min at RT in the dark.  
21. Add 150 µL of Perm/Wash Buffer per well and mix by gently pipetting at least 3 
times. 
22. Centrifuge at RT at 670g for 3 min. 
23. Quickly flick into sink and immediately invert the plate on a paper towel. 
24. Add 200 µL of Perm/Wash Buffer per well and mix by gently pipetting at least 3 
times. 
25. Centrifuge at RT at 670g for 3 min. 
26. Quickly flick into sink and immediately invert the plate on a paper towel. 
Note: If staining for surface markers, then proceed to next section "Staining for 
Surface Markers". If not proceed to step 27. 
27. Resuspend the cell pellet in 200 µL of 1× PBS (Recipe 9).  
28. Transfer the cell suspension from wells to FACS tubes.  
Note: The samples can be stored at 4°C in the dark for 24 hours  until flow 
cytometry acquisition. 
Staining for surface markers  
One fundamental application flow cytometry is the discrimination of cell types based 
on the differential abundance or presence of surface proteins. Cells may be stained for 
intracellular phosphorylated proteins and stained for surface markers, allowing 
differences in signalling responses in mixed populations of cells to be resolved.  
Before choosing to label for surface markers, it should be noted that many cell surface 
markers are sensitive to fixation and permeabilization procedures and will not be 
recognized by the relevant antibodies afterward such procedures. Thus, we 
recommend that surface marker labelling under the conditions required for 
intracellular labelling be tested prior to performing this type of analysis.  
In order to perform multiparameter analysis of intracellular and surface proteins, the 
cell surface antigen must be recognized with antibodies that are directly conjugated to 
a fluorochrome. The fluorochromes should have minimal spectral overlap. Additional 
controls are also required compared to the detection of only the intracellular 
phosphoprotein. The additional controls are necessary for correctly setting 
compensation parameters, especially if a spectral overlap exists. Single-labeled and 
multi-labeled controls are needed to ensure correct parameters. They are set to 
optimize cell number and minimize detector overlap. 
1. To the appropriate wells 100 µL of directly conjugated antibody solution (Recipe 
13) per well and mix by gently pipetting at least 3 times.  
Note: This step follows step 26 in the preceding section.  
2.   Incubate for 15 min at RT in the dark.  
3.  Add 150 µL of PBS (Recipe 9) per well and mix by gently pipetting at least 3 
times. 
4.  Centrifuge at RT at 670g for 3 min. 
5.  Quickly flick into sink and immediately invert the plate on a paper towel. 
6.  Add 200 µL of PBS (Recipe 9) per well and mix by gently pipetting at least 3 
times. 
7.  Centrifuge at RT at 670g for 3 min. 
8.  Quickly flick into sink and immediately invert the plate on a paper towel. 
9.  Resuspend the cell pellet in 200 µL of PBS (Recipe 9) and transfer the cell 
suspension from wells to FACS tubes.  
Note: The samples can be stored at 4°C in the dark for 24 hours until flow 
cytometry acquisition. 
Flow Cytometry Analysis 
This procedure is based on the use of a FACs Can flow cytometer, but can be adapted 
to similar equipment. This procedure requires prior familiarity with flow cytometry 
techniques and instrumentation. 
Flow cytometer setup 
1.  Turn on the flow cytometer and computer and wait at least 15 min for the lasers to 
warm up.  
2. Remove samples from the fridge, if necessary, and keep samples in the dark at RT. 
3.  Launch the acquisition software by choosing ‘Open 
Detectors/Amps/Threshold/Compensation’ from the cytometer menu and open a 
folder to store the files. 
4.  Place a FACS tube containing 500 µL Flow Cytometer Calibration Beads (Recipe 
9) and acquire about 2,500 events corresponding to single beads in a forward-by-side 
scatter /side scatter FCS/SSC dot plot using FL2 settings suitable for human test cells 
(as indicated by FACS supplier’s information). 
Note: Beads should be mixed well prior to use.   
Data acquisition by flow cytometry 
Data acquisition parameters depend on if the samples were stained for a single 
phosphorylated protein or if multiparameter staining was performed. For single 
staining experiments, a dot plot showing forward-by-side scatter /side scatter 
(FSC/SSC) is constructed to bring cells on scale, a gate is set around the cell 
population of interest (possibly all cells), and a histogram showing FL2, the PE 
channel, is generated to display only events in the defined gate (Fig. 4).  
For multiparameter staining, additional set up is required. In addition to a dot plot 
showing FSC/SSC for bringing the cells on scale and setting the gates around the cell 
population of interest (possibly all cells) (Fig. 5A), a second a dot plot is constructed 
from the intensity of the staining of the two surface markers. This second dot plot is 
used to discriminate the different cell types based on the differential expression of 
surface proteins (Fig. 5B). Gates are set to identify the population(s) of interest, and 
then a histogram is constructed showing FL2 to display only events within the 
corresponding gate (Fig. 5 C,D,E). A compensation procedure is also necessary. The 
procedure below assumes that FITC is detected in FL1, PE in FL2, and Cy5 in FL3 
and that cells labelled with only a single fluorochrome, such as FITC, PE, or Cy5, are 
at least as bright, and preferably brighter, than the brightest test samples expected. 
Note: You cannot correctly set up compensation with dimly stained cells. 
1.  Construct the appropriate data acquisition settings file to run samples or open the 
data acquisition settings file if available. 
2. Set the FCS/SSC amplifier to linear mode and FL1, FL2, and FL3 amplifiers to 
logarithmic mode. 
Note: For single stain set FCS/SSC amplifier to linear mode and FL2amplifier 
to logarithmic mode  
3. Place a FACS tube containing UT sample plus the isotype control antibody for the 
FITC-, PE-Cy5- surface directly conjugated antibodies and for PE- intracellular 
antibody 
Note: For single stain place a FACS tube containing UT sample plus the I
 sotype control antibody  
Note: Mix cells on a vortex at mediums speed and then introduce samples into 
the flow cytometer. 
4.  Start data acquisition in setup mode.  
5.  If necessary, adjust the FSC and SSC detectors to place the cell populations on the 
dot plot by first adjusting the voltage settings on the FSC and SSC detectors and then 
adjusting the threshold to remove "debris" and noncellular elements.  
Note: This is done from the flow cytometer menu for the acquisition of cells. 
5. Draw a gate around the cell population of interest (possibly all cells). 
6. Refer to the FL2 versus FL1 plot and adjust the voltage on the FL1 detector to 
position the negative cell population in the first decade of the log scale median 
fluorescence intensity (MFI) of FL1, then adjust the voltage on the FL2 detector to 
position the negative cell population in the first decade of the log scale MFI FL2. 
7. Refer to FL3 versus FL2 plot and adjust the voltage on the FL3 detector to position 
the negative cell population in the first decade of log scale MFI FL3.  
Note: For single stain refer to the histogram showing FL2 to display only 
events in the gate and adjust the voltage on the FL2 detector to position the 
negative cell population in the first decade of the log scale MFI of FL2.  
8. Place a FACS tube containing UT sample plus FITC- directly conjugated antibody 
against the target surface marker only (for compensation) 
Note: Mix cells on a vortex at mediums speed and then introduce samples into 
the flow cytometer.  
9. Refer to the FL2 versus FL1 plot and adjust the FL2-%FL1 compensation control to 
bring the FITC-only cell population to the point that the FL2 median of this population 
is approximately the same as the FL2 median of the negative cells.  
Note: This is typically moving the cells downward on the plot.  
10. Place a FACS tube containing UT sample plus PE-Cy5- directly conjugated 
antibody against the target surface marker only (for compensation) 
Note: Mix cells on a vortex at mediums speed and then introduce samples into 
the flow cytometer 
11. Refer to the FL3 versus FL2 plot and adjust the FL2 - %FL3 compensation control 
to bring the PE-Cy5-only cell population to the point that the FL2 median of this 
population is approximately the same as the FL2 median of the negative cells.  
Note: This is typically moving the cells leftward on the plot.  
12. Place a FACS tube containing UT sample plus PE- antibody against the target 
phosphoprotein only (for compensation) 
Note: Mix cells on a vortex at mediums speed and then introduce samples into 
the flow cytometer 
13. Refer to the FL2 versus FL1 plot and adjust the FL1 - %FL2 compensation control 
to bring the PE-only cell population to the point that  the FL1 median of this 
population is approximately the same as the FL1 median of the negative cells. 
 Note: This is typically moving the cells leftward on the plot.  
14. Refer to the FL3 versus FL2 plot and adjust the FL3 - %FL2 compensation control 
to bring the PE-only labeled cell population to the point that the FL3 median of this 
population is approximately the same as the FL3 median of the negative cells. 
Note: This is typically moving the cells downward on the plot.  
Note: Steps 8 through 14 represent the compensation procedure. If the voltage 
is changed on any of the three detectors after this is done, then the 
compensation procedure must be repeated.  
Note: Steps 8 through 14 are the compensation procedure and only apply to 
multiparameter experiments. For single staining experiments, proceed to steps 
1 through 7.  
12.  Start data acquisition in acquire mode and acquire data for a minimum of 2,500 
gated events of a minority cell population of interest.  
13.  Adjust the gate around the cell population of interest (possibly all cells) if 
necessary.  
14.  Clean the machine with bleach and water, leave it on standby or shut down. 
Note: Data analysis can be performed any time after acquisition has been 
finished.  
Dynamic phosphoflow data analysis 
1. From the flow cytometry data analysis software program, create a window with dot 
plots and histograms (see Fig. 4 and 5 for example) and then open the file to be 
analyzed. 
Note: Once the process has been done once a template can be created for 
dynamic phosphoflow analysis and used instead of creating a window with the 
plots and histograms each time.  
2.  Drag the gates over the correct populations. For single stain, drag the gate over the 
population in the FSC/SSC dot plot. Set a gate around each population in which you 
are interested (possibly all cells) and a histogram showing FL2 to display only events 
in the defined gate (Fig. 4). 
For multicolor stain, drag the gates over the correct populations in the dot plot in 
which you are interested and histograms showing FL2 to display only events in the 
above gates (Fig. 5). 
3. Check if all FL2  histograms are compatible with single populations of cells, if 
needed (with a small number of cells and/or noise events) adjust gates or place 
markers around the peaks. 
Note: It is normal practice to set a gate on displays of fluorescent parameters 
using a region around a selected population defined on a FSC/SSC plot. 
However, occasionally, it is unclear as to where the region should be drawn. 
In such cases, a back gating is performed. For this draw a region on a 
fluorescence parameter, which defines the population of interest, and the 
region used to set a gate on FCS/SSC plot. The scatter can now be seen more 
clearly so that the correct region can be set, in turn, to use as a gate in the 
normal manner..  
4.  Select all plots and histograms and copy them to a Microsoft Word document. 
5. From the CellQuest or FlowJo document, transfer MFI values corresponding to 
phosphorylation of the signaling protein for each tested condition (UT, pV, Inhibitor), 
cell types, and phosphoproteins analyzed to a Microsoft Excel file for calculations. 
6. Calculate, in Microsoft Excel, for cell types and phosphoproteins analyzed, relative 
phosphorylation. For pervanadate-treated samples, calculate this as  
Relative phosphorylation = MFI UT /MFI pV 
For kinase inhibitor-treated samples, calculate this as  
Inhibition (%) = [1- (MFI Inhibitor/MFI UT)] × 100 
7. Construct, in Microsoft Excel, a graph corresponding to relative phosphorylation or 
to inhibition in function of cell types and phosphoproteins analyzed (see Fig. 6A and 
B for examples).  
 
RELATED TECHNIQUES 
Several methods are available for measuring the phosphorylation analysis 
(phosphoproteomics) of signaling proteins. Conventional methods, such as 
immunoprecipitation followed by immunoblotting or immunofluorescence microscopy 
with antibodies that specifically recognize phosphorylated proteins, have provided a 
wealth of information about cell signaling, but generally permit the analysis of a few 
signaling molecules per experiment. Futhermore, these methods have several 
important limitations (1). The stoichiometry of phosphorylation is usually very low , 
where all the cells from a cell population are not responding at the same time and/or 
relative few proteins in the total are phosphorylated. Some signaling molecules are 
present at low abundance within cells (10)and phosphorylated proteins may be 
underdetected unless  protein phosphatase activity is adequately inhibited during 
preparation and purification steps of cell lysates. Moreover, these methods are 
laborious, time consuming, and difficult to adapt for high-throughput analysis (11). 
Mass spectrometry methods overcome many of the limitations of the conventional 
biochemical techniques (12-14). These methods are very powerful to analyze signaling 
events in large scale into a cell population. However, cells may develop individual 
flux of signaling events that is buried in the lump of data generated at the cell 
population level. 
Detecting signaling at the single cell level is a critical challenge to probe single cell 
responses (15). By using a microfluidics device combined with immunocytochemistry, 
microfluidics techniques allows analysis based on phosphorylation-specific antibodies 
and can be applied to single-cell analysis  (16). However, this method has been 
reported only for adherent-cell signaling experiments. 
Phospho-flow proteomics are methods that combine phosphorylation-specific 
antibodies with flow cytometry. One approach employs flow cytometry to analyze cell 
or tissue lysates with a cytometric bead array (17). Garry Nolan’s group at Stanford 
University (http://proteomics.stanford.edu/nolan/) has developed phospho-flow 
proteomic methods that allow  analysis of phosphoproteins in single cells (18)Cite 
Krutzik et al. Nat. Chem. Biol. 2008 or some other primary literature here ). With this 
approach one can correlate intracellular signaling events with discrete subpopulations 
of cells.  
Signaling events are dynamic and phosphorylation sites exist at very low 
stoichiometric levels (19). Further confounding analysis, is that , in most cases, 
phosphorylation is a transient and a reversible event (11).  The consideration of 
signaling networks as dynamic systems is crucial and requires methods applicable for 
the analysis of individual living cells (20).  
One way to discern signaling networks that are unique to cancer cells is to expose the 
cancer cells  to potentiating inputs, rather than relying upon the basal amounts of 
protein phosphorylation alone (21). Lymphocyte subsets from normal donors exhibit 
little donor-to-donor variation in cytokine-induced phosphoprotein responses  (21). In 
contrast, the responses of cells from acute myeloid leukemia (AML) patients varied in 
numerous ways from one patient to another and were different from normal donors. 
Our method does not rely on cytokine stimulation and thus should avoid the issues 
related to donor variability. Just as single-cell phosphoflow proteomics have been used 
for drug screening by measuring the phosphorylation state of endogenous proteins 
following exposure to cytokines (18), our dynamic phosphoflow analysis can also be 
applied to drug discovery.  
 
NOTES AND REMARKS 
We present three examples that illustrate the application of the dynamic phosphoflow 
method. We performed phosphoflow analysis to determine whether a signaling 
pathway is constitutively activated (signaling "on") or not (signaling "off") by 
analyzing the serine phosphorylation of Akt at the position 473 (Ser473) and tyrosine 
phosphorylation of CrkL at the position 207 (Tyr207) in the T cell line HUT78 that has 
functional PTEN (phosphatase and tensin homolog) (4, 22)) and the U937 myeloid 
cell line that is deficient in PTEN (4, 22) (Fig. 4). Cells deficient in PTEN exhibit 
basal activation of the PI3K/ Akt pathway (3). These two cell lines serve ascontrol 
cells: HUT78 cells should be phosphoAkt negative (PI3K/Akt signaling should be 
relatively low, "off") and U937 cells should be phosphoAkt positive (PI3K/Akt 
signaling high, "on").  
To show that this method can reveal information about cells for which the state of the 
signaling pathway is unknown, we compared the results obtained with the U937 and 
HUT78 cells with those obtained with the chronic myeloid leukaemia (CML) cell line 
K562 that is PTEN positive, but for which the status of basal phosphorylation of Akt 
on Ser473 is controversial (22, 23). The Akt phosphorylation profile of K562 was 
similar to the PTEN-deficient cell line, U937 (grey histograms). Moreover, when 
K562 or U937 cells were treated with pervanadate, the increase in Akt 
phosphorylation was low, consistent with this pathway  active under basal conditions 
(red curves, Fig. 4B). Relative phosphorylation, which corresponds to phosphorylation 
quantitation changes in response to pervanadate, was calculated for the HUT78, U937, 
and K562 cells. A positive threshold was defined as 0.3, which was based on the mean 
+ 2 standard deviations of relative phosphorylation of the HUT78 cells (Fig. 6A). 
Thus, the pathway was considered "on" if the relative phosphorylation values 
exceeded 0.3. Indeed, the relative phosphorylation values of the U937 and K562 cells 
were 0.7 and 0.5, respectively, thus, the “test” cells (K562 cells) exhibit basal activity 
of the PI3K pathway.  
The K562 cells also serve as a positive control for analysis of the activity of the 
oncoprotein tyrosine kinase BCR-ABL, which is present in K562 cells (24), but not in 
U937 or HUT78 cells. We assayed the phosphorylation status of the adaptor protein 
CrkL, which is phosphorylated by BCR-ABL, in these three cell lines and, as 
expected, high basal phosphorylation of CrkL was only detectable in K562 cells (Fig. 
4B) and the increase of phosphorylation with pervanadate is low (Fig. 4B, red curve 
versus grey histogram). Thus the relative CrkL phosphorylation in K562 cells 
(calculated as MFI UT/ MFI pV is high  (Fig. 6A). 
We also illustrated how with the combination of intracellular phosphorylation-state 
labeling and extracellular surface marker labeling can differentiate the activity of a 
signaling pathway in a population of mixed cells. We performed multiparameter 
labeling by combining direct extracellular staining with intracellular phosphoprotein 
staining of a mixed cell population containing 20% HUT78 T cells (Akt signaling off, 
CD3 positive) and 80% U937 myeloid cells (Akt signaling on, CD13 positive) (Fig. 
5). Cells were treated or not with different agents (wortmannin and pervanadate) and 
then fixed and permeabilized, stained with antibody against phosphoAkt (Ser473) 
detected by the sandwich method, and stained with a mixture of antibodies against 
CD3 (conjugated to PE-Cy5) and CD13 (conjugated to FITC). By selecting all living 
cells (Fig. 5A), the HUT78 cells are difficult to detect (Fig. 5C). However, by 
selecting independently the two cell types based on their surface markers, CD3 or 
CD13 (Fig. 5B), the cell-specific status of the phosphorylation of Akt Ser473 becomes 
resolvable (Fig. 5D-E). Moreover, treatment of the cells with the PI3K inhibitor 
(wortmannin) does not change the Akt Ser473 phosphorylation status in HUT78 cells 
(Fig. 5E, blue curve versus grey histogram), but substantially decreases the basal Akt 
Ser473 phosphorylation state in U937 cells (Fig. 5D, blue curve versus grey histogram).  
To demonstrate the potential usefulness in drug development and assessment of the 
specificity of inhibitor activity, we examined the effects of wortmannin on the 
phosphorylation of the BCR-ABL target CrkL, which is not known as downstream of 
PI3K. The high phosphorylation of Akt in U937 and K562 cells was largely decreased 
(Fig. 7, upper histograms) by wortmannin; however, wortmannin failed to decrease the 
phosphorylation  CrkL in K562 cells (Fig.7, lower histograms), showing that WMN 
doesn’t affect the Bcr-Abl tyrosine kinase activity in K562 cells. Phosphorylation 
inhibition was quantified (Fig. 6B). A positive threshold was defined from on the basis 
of the HUT78 cells as 51%, which is consistent with previously considered threshold 
(25). The percent inhibition in the U937 and K562 cells exceeded this threshold at 
76% and 77%, respectively. Thus, both the pervanadate data and the wortmannin data 
suggest that Akt is basally active in these cells and the wortmannin data further 
suggest that PI3K is implicated in the phosphorylation of Akt Ser473. 
These examples illustrate the potential utility of this protocol to investigate the basal 
activaty of signaling pathways at the single-cell level, to develop kinase- or 
phosphatase-targeted drugs, and elucidate potential new targets of existing drugs. This 
dynamic approach by modulation positive and negative of kinases and phosphatases 
that are involved in signaling cascades, in combination with the signal amplification 
through a sandwich labeling method, increases the accuracy and reproducibility of the 
measurements compared to a single analysis without treatment with pleitropic 
activators of signaling pathways. 
 
Fig. 1. Example of how phosphorylation status can be assessed with pervanadate or 
specific kinase inhibitors by dynamic phosphoflow cytometry. (A) Example of how 
the basal activity of a kinase affects the change in a target protein's phosphorylation 
induced by pervanadate. (B) Example of how the basal activity of a kinase affects the 
change in a target protein's phosphorylation state in the presence of a specific kinase 
inhibitor. 
Fig. 2. Diagram of the sandwich method for amplifying antibody labelling signals. 
 
Fig. 3. Schematic representation of phosphoprotein staining in a 96-well plate.  
Staining is performed in 96-well round bottom microtiter plates. These schemes are 
drawn for the analysis of one phosphoprotein (A) in a single intracellular labelling 
(targeting phosphoprotein) or (B) in a double intracellular and cell surface staining 
(targeting surface markers and phosphoprotein).  
Plate A : position A-1 = untreated (UT) sample plus isotype control, position C-1 = 
UT sample plus phosphoprotein staining, position E-1 = inhibitor (pervanadate or 
wortmannin)-treated sample, plus phosphoprotein staining. 
Plate B : position A-1 = UT sample plus isotype controls, position C-1 = UT sample 
plus phosphoprotein and cell surface markers staining, position E-1 = inhibitor-treated 
sample, plus phosphoprotein and cell surface markers staining. Several staining 
controls are added with UT sample for setting compensation: position B-3 = FITC-
only (first cell surface marker staining alone), position B-5 = PE-Cy5 only (second 
cell surface marker staining alone), position B-7 = PE-only (phosphoprotein staining 
alone).  
 
Fig. 4 Example of dynamic phosphoflow  cytometry to determine in the  
phosphorylation state of a single protein. The activity of PTEN (an inhibitor of the 
PI3K pathway) and Bcr-Abl (kinase that phosphorylates CrkL) in the various cell lines 
is indicated. The phosphorylation state of Akt (Ser473) and CrkL (Tyr207) was 
measured by phosphoflow analysis. (A) Intact cells were gated on scatter properties. 
(B) Each histogram shows the staining of untreated sample (UT) as the grey histogram 
and the sample treated with pervanadate (pV) as a red line histogram. MFI, mean 
fluorescence intensity. Relative phosphorylation was quantified as ratio MFI = R = 
MFI UT / MFI pV.  
 
Fig. 5. Example of multiparameter analysis to determine phosphorylation state of Akt 
from a mixed cell population using cell surface marker labelling. The abundance of 
phosphorylated Akt at Ser473 (pAkt)in response to pervanadate and wortmannin of a 
mixed culture of U937 and HUT78 cells (ratio 4:1) was assayed. pAkt was detected 
with the phosphorylation-state specific antibody and CD3 and CD13 monoclonal 
antibodies were used to label T cells (HUT78) and cells of myeloid lineages (U937), 
respectively. MFI, mean fluorescence intensity. (A) Intact cells were gated on scatter 
properties. (B) Cells were gated based on the presence of CD3 and CD13. (C-E) Each 
histogram shows the staining of untreated sample (UT) as the grey histogram, 
pervanadate-treated samples (pV) as a red line histogram, and wortmannin (WMN)-
treated samples  as a blue line histogram. Relative phosphorylation R and 
phosphorylation inhibition I (%) values appear in the histograms. (C) Analysis of the 
mixed U937 and HUT78 cell response. (D) The U937-specific cell response. (E) The 
HUT78-specific cell response.  
Fig. 6. Quantitation of Akt and CrkL phosphorylation in response to pervanadate 
treatment (A) or wortmannin treatment (B) from independent experiments with single 
phosphoprotein labelling. In A, the relative phosphorylation R was quantified as ratio 
MFI = R = MFI untreated (UT) / MFI pervanadate pV [n = 25 HUT78;  n = 25 U937; 
n = 2 K562] are reported in the graph. Columns are the mean + SD of average R 
values. In B, phosphorylation inhibition was quantified as Inhibition (%) = I (%) = 1 – 
(MFI WMN / MFI UT). Quantitation of Akt and CrkL phosphorylation inhibition 
from independent experiments [n = 25 HUT78; n = 25 U937; n = 2 K562] are reported 
in the graph. Columns are the mean + SD of average I (%) values.  
 
Fig. 7. Example of dynamic phosphoflow cytometric analysis of cell lines treated with 
the cell signalling inhibitor wortmannin (WMN), a PI3K inhibitor. The known activity 
of PTEN and Bcr-Abl, as well as the predicted basal phosphorylation state of Akt and 
CrkL are indicated. Intact cells were gated on scatter properties (not shown) and each 
histogram shows the staining of untreated sample (UT) as the grey histogram, WMN-
treated sample as a blue line histogram. MFI, mean fluorescence intensity. 
Phosphorylation inhibition was quantified as Inhibition (%) = I (%) = 1 – (MFI WMN 
: MFI UT).  
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